Odyssey Therapeutics

Odyssey Therapeutics

Odyssey Therapeutics launched in 2019 under founder and CEO Gary Glick, a veteran chemist who previously built and sold IFM Therapeutics to Bristol-Myers Squibb. The firm operates from Boston, a hub for biotech platform companies, and emerged as a conspicuously well-capitalized startup with a $218 million Series B in 2021 led by OrbiMed, SR One, and Logos Capital. Its mandate fuses computational target discovery with internal drug development rather than out-licensing early-stage assets. The firm applies machine learning and functional genomics across immunology and oncology. Its pipeline centers on small-molecule inhibitors and protein degraders for targets in inflammasome biology and tumor microenvironment pathways. Co-investors and syndicate partners in its rounds have included Fidelity Management & Research, Matrix Capital Management, and T. Rowe Price Associates, alongside crossover funds General Catalyst and Woodline Partners (per the firm's SEC filings, 2021). Odyssey pursues programs across the US and Europe through CRO partnerships. Odyssey has not disclosed its total headcount but recruited senior leadership from Novartis, Jnana, and Celgene. No adjacent philanthropic or real-asset vehicles are publicly known. In May 2023, the firm named former Novartis Institutes for BioMedical Research executive Don Nicholson as Chief Scientific Officer (per the firm, May 2023), reinforcing its orientation toward an asset-centric biotech model rather than a platform-licensing shop. The structural differentiator is Odyssey's full-stack model: it integrates computational biology for target identification with an internal medicinal chemistry group, retaining economic interest across discovery through clinical proof-of-concept instead of the standard early-partnering approach common to biotech platforms. This hybrid architecture makes it function less like a CRO-dependent virtual biotech and more like a capital-efficient pharma discovery unit.